MPS Limited has submitted annual compliance confirmations to BSE Limited and National Stock Exchange of India Limited on 17 April 2026, affirming adherence to SEBI exemption orders for the financial year ended 31 March 2026. The confirmations relate to two family trusts that hold exemptions under the SEBI Substantial Acquisition of Shares & Takeovers Regulations, 2011.

SEBI Exemption Orders and Compliance Status

Two separate family trusts have maintained compliance with their respective SEBI exemption orders throughout FY26:

Both trusts received exemptions from complying with Regulations 3 and 4 of the Takeover Regulations regarding their proposed acquisition and exercise of voting rights in MPS Limited. The exemptions were granted under Regulation 11(5) of the SEBI Takeover Regulations 2011.

Independent Auditor Certification

As required by the SEBI exemption order conditions, independent auditor certification has been obtained for both trusts. Jain Kapil & Associates, Chartered Accountants (Firm Registration Number: 037228C), issued certificates dated 15 April 2026 confirming complete compliance with the respective SEBI exemption orders.

Regulatory Framework and Documentation

The compliance confirmations were submitted under the powers conferred upon SEBI under Section 19 of the Securities and Exchange Board of India Act, 1992, read with Regulation 11(5) of the Takeover Regulations. The original SEBI exemption orders have been enclosed as supporting documentation.

For NAFT, the relevant condition is specified in Para 5(x) of the exemption order, while for NAFT-2, the requirement falls under Para 4(g)(x). Both conditions mandate annual compliance certification from independent auditors.

Trustee and Reporting Structure

Nishith Arora serves as the trustee for both family trusts and has digitally signed the compliance confirmations. The reports have been filed with:

• BSE Limited and National Stock Exchange of India Limited
• Securities & Exchange Board of India
• MPS Limited

The annual compliance confirmation represents a mandatory regulatory requirement to maintain the exemption status granted by SEBI for the family trusts' holdings in MPS Limited. This ensures continued adherence to the specific conditions outlined in the original exemption orders while maintaining transparency with market regulators and stakeholders.

MPS Pharmaa Limited has filed its mandatory quarterly investor complaint statement with BSE Limited for the quarter ended 31st March, 2026, reporting a clean record with zero complaints across all categories. The pharmaceutical company, formerly known as Advik Laboratories Limited, submitted the disclosure in compliance with Regulation 13(3) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Quarterly Complaint Summary

The company's investor complaint statement for Q4FY26 demonstrates complete absence of grievances from shareholders during the reporting period:

Regulatory Compliance

The statement was formally submitted to BSE Limited on 13th April, 2026, and was digitally signed by Company Secretary Pooja Chuni. The disclosure fulfills the company's obligation under SEBI regulations to maintain transparency regarding investor grievances and complaint resolution mechanisms.

Company Details

MPS Pharmaa Limited operates under BSE Scrip Code 531686 and ASE Scrip Code 01636. The company maintains its corporate office at Arunachal Building, Barakhamba Road, Connaught Place, New Delhi, while its registered office and manufacturing facility are located in the Roz-Ka-Meo Industrial Area, Sohna, Haryana.

The zero complaint record for Q4FY26 indicates effective investor relations management and suggests minimal shareholder concerns during the quarter. This regulatory filing demonstrates the company's commitment to maintaining transparent communication with stakeholders and adhering to prescribed disclosure norms.